Jonathan Heller, Ph.D. is the founder and CEO of Teton Therapeutics, Inc. Teton is dedicated to the development of new medicines that dramatically improve the lives of patients and families with neurofibromatosis.
Jonathan has been building company pipelines by leading drug and business development efforts for over 15 years. His focus has been on rare disease and oncology with roles of increasing responsibility at Pfizer, Synageva, and BioMarin. Among his accomplishments is the preclinical development of BioMarin’s Brineura and Vosoritide, the first ever treatments for late infantile neuronal ceroid lipofuscinosis and achondroplasia. Jonathan began his industry career leading scientific efforts at Erimos Pharmaceuticals, a company started to develop the oncology drugs Jonathan discovered while a graduate student at The Johns Hopkins University.
Jonathan has an MBA from The University of California at Berkeley, a PhD in biology from The Johns Hopkins University, and a BA in Biochemistry and Molecular Biology from Reed College.